Review finds thin evidence for off-label semaglutide and tirzepatide uses
A new review says signals for semaglutide and tirzepatide outside their approved uses rest mostly on lab and observational data, not randomized trials, so questions about benefit and risk stay open.
A review published July 21, 2026 in the journal Biomedicines concludes that evidence supporting unconventional uses of semaglutide and tirzepatide is limited across five areas: oncology, psychiatry and addiction medicine, orthopedics, aesthetic medicine, and human reproduction [1].
The paper, "Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction," was written by Sandro La Vignera and Rosita A. Condorelli of the Department of Clinical and Experimental Medicine at the University of Catania in Italy [1]. It was submitted May 31, 2026, revised June 25, 2026, accepted July 8, 2026 and published July 21, 2026 as article 1644 in volume 14, issue 7 of the journal [1]. It appears in the journal's collection of Feature Papers in Obesity, Type 2 Diabetes and Metabolic Syndrome [1].
What the review reports
The review describes signals in each of the five domains it covers. In oncology, it points to antitumor activity that may work through the tumor immune microenvironment, metabolic reprogramming, angiogenesis and apoptotic pathways [1]. In psychiatry and addiction medicine, it describes effects on mesolimbic dopamine reward pathways, GABAergic neurotransmission and stress-response systems, which the authors link to alcohol use and binge-eating disorders [1]. In orthopedics, it covers knee osteoarthritis pain and function, describing effects on bone metabolism, cartilage homeostasis and joint inflammation through both direct receptor-mediated and indirect weight-loss-dependent mechanisms [1]. In aesthetic medicine it addresses inflammatory skin disease, and in human reproduction it covers polycystic ovary syndrome, or PCOS, and male fertility [1].
The authors' central conclusion is that across all five domains, the evidence derives predominantly from preclinical models, observational cohorts and pharmacoepidemiologic studies, with randomized trials remaining limited [1].
Specific effect sizes and patient counts for these uses have not been reported in the review [1]. The review also does not state whether regulators in the United States or elsewhere have reviewed any of these uses, and no individual study results are summarized in the published citation record [1].
Why it matters for patients
People taking semaglutide (sold as Ozempic, Wegovy and Rybelsus) or tirzepatide (sold as Mounjaro and Zepbound) may encounter news coverage suggesting these drugs could treat cancer, curb alcohol use, ease arthritis pain, calm inflammatory skin conditions or improve fertility. This review's bottom line is that those ideas are still early-stage: the supporting evidence is drawn mostly from laboratory work, observational groups of patients and large database studies that track patterns of use [1].
Those study designs can show associations, but they cannot establish that the drug caused an outcome the way randomized controlled trials can. Because randomized trials in these areas remain limited [1], there is not yet reliable information about how much benefit, if any, patients would see, or what risks might come with using these drugs for reasons other than their approved indications.
That gap matters for decisions about cost and coverage as well. This review does not address insurance coverage or what any health plan pays for, so it has not been disclosed whether these uses would be covered [1].
What happens next
No specific trials or completion dates for these five areas are named in the review [1]. The authors' stated finding is that randomized evidence remains limited across all of the domains they examined [1], which means the question of whether these uses hold up in controlled studies has not yet been answered.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.